Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

UBTF tandem duplication AMLs are sensitive to menin inhibition

ABSTRACT: To investigate the effect of Menin inhibitor on UBTF-TD harboring AML. We characterized UBTF-TD interaction with KMT2A and Menin in different leukemia models including KMT2A-r, transduced and normal cbCD34+ cells as well as in primary AML cells with UBTF-TD mutation. We also analized gene expression pattern upon treatment with Menin inhibitor.

ORGANISM(S): Homo sapiens

PROVIDER: GSE233810 | GEO | 2023/12/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

UBTF tandem duplication acute myeloid leukemias are sensitive to menin inhibition [RNA-seq]

Project description:UBTF tandem duplications (TD) have recently emerged as a subtype-defining alteration in pediatric acute myeloid leukemia (pAML), which is characterized by HOXB gene dysregulation and a poor response to conventional chemotherapy. Here, we use protein-protein interaction studies to show that UBTF-TD maintains interactions with components of the RNA pol I complex, while also engaging with a network of unique protein interactors specific to UBTF-TD, like KMT2A. These data suggest that UBTF- TD both preserves canonical UBTF functions and demonstrates gain of function activities. Furthermore, we show that UBTF-TD and KMT2A co-localize to key genomic targets dysregulated in UBTF-TD myeloid malignancies, like HOXB gene clusters and MEIS1. Using a protein degradation system, we show that stemness, proliferation, and the HOXB molecular signature are dependent on sustained UBTF-TD localization to chromatin. Finally, we show UBTF-TD leukemias are sensitive to menin inhibition—providing a viable therapeutic strategy for children with this high-risk AML subtype.

2024-02-12 | GSE229663 | GEO

UBTF tandem duplication acute myeloid leukemias are sensitive to menin inhibition [Cut&Run]

2024-02-12 | GSE229664 | GEO

UBTF tandem duplication AMLs are sensitive to menin inhibition

Project description:UBTF tandem duplication AMLs are sensitive to menin inhibition

| PRJNA978037 | ENA

UBTF tandem duplication defines High-risk Pediatric Acute Myeloid Leukemia

Project description:Genomic profiling of relapsed pediatric AML demonstrated an increase in KMT2A and NUP98 rearrangements when compared to de novo pediatric AML, as well as an increase in WT1 mutations. Notably, we identified recurrent (9% of relapse cohort) exon 13 duplications in UBTF in pediatric AML cases that previously lacked known driver alterations. These UBTF-tandem duplication (TD) pediatric AMLs occur in approximately 4% of all pediatric AMLs and are less common in adult AMLs, are associated with normal karyotype or trisomy 8 cytogenetic abnormalities, co-occur with WT1 and FLT3-ITD, have an expression profile similar to NUP98-NSD1 and NPM1 mutant AMLs and are independently associated with poor outcome.

| EGAS00001005760 | EGA

Expression data from cord blood CD34+ cells transduced with UBTF wildtype expression vectors, UBTF-TD expression vectors, or empty control vector.

Project description:UBTF tandem duplications (UBTF-TD) were identified frequently in relapsed pediatric acute myeloid leukemia. The purpose of this study is to investigate the functional consequence of the overexpression of UBTF-TD in normal cord blood CD34+ cells.

2022-02-22 | GSE189901 | GEO

UBTF tandem duplication acute myeloid leukemias are sensitive to menin inhibition

Project description:UBTF tandem duplication acute myeloid leukemias are sensitive to menin inhibition

| PRJNA955252 | ENA

UBTF tandem duplication acute myeloid leukemias are sensitive to menin inhibition [Cut&Run]

Project description:UBTF tandem duplication acute myeloid leukemias are sensitive to menin inhibition [Cut&Run]

| PRJNA955261 | ENA

UBTF tandem duplication acute myeloid leukemias are sensitive to menin inhibition [RNA-seq]

Project description:UBTF tandem duplication acute myeloid leukemias are sensitive to menin inhibition [RNA-seq]

| PRJNA955243 | ENA

Mezigdomide is effective alone and in combination with Menin inhibition in Acute Myeloid Leukemia

Project description:Small molecules that target the MENIN-KMT2A protein-protein interaction (Menin inhibitors) have recently entered clinical trials in lysine methyltransferase 2A (KMT2A, MLL1) rearranged (KMT2A-r) and nucleophosmin mutant (NPM1c) acute myeloid leukemia (AML) and are demonstrating encouraging results. However, rationally chosen combination therapy is needed to improve responses and prevent resistance. We have previously identified IKZF1/IKAROS as a target in KMT2A-r AML and shown in preclinical models that IKAROS protein degradation with Lenalidomide or Iberdomide has modest single-agent activity yet can synergize with Menin inhibitors. Recently, the novel IKAROS degrader Mezigdomide was developed and has greatly enhanced IKAROS protein degradation. In this study we show that Mezigdomide has increased preclinical activity in vitro as a single-agent in KMT2A-r and NPM1c AML cell lines, including sensitivity in cell lines resistant to Lenalidomide and Iberdomide. Further, we demonstrate that Mezigdomide has the greatest capacity to synergize with and induce apoptosis in combination with Menin inhibitors. We show that the superior activity of Mezigdomide compared to Lenalidomide or Iberdomide is due to its increased depth, rate, and duration of IKAROS protein degradation. Single-agent Mezigdomide was efficacious in five patient derived xenograft (PDX) models of KMT2A-r and one NPM1c AML. The combination of Mezigdomide with a Menin inhibitor increased survival and prevented the development of recently described MEN1 mutations. These results support prioritization of Mezigdomide for early phase clinical trials in KMT2A-r and NPM1c AML, either as a single-agent or in combination with Menin inhibitors.

2024-02-15 | PXD041735 | Pride

Mezigdomide is effective alone and in combination with Menin inhibition in Acute Myeloid Leukemia

2024-02-15 | PXD041737 | Pride